Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 12/20 | 0.43 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.33 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.32 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.32 |
| ▸ | CASR | P41180 | 2/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5782157 | 1.00 | CRHR1 (0.43) | CRHR1BRD9BRD7NTRK1FFAR2 | |
| SCHEMBL6499773 | 1.00 | CRHR1 (0.43) | CRHR1BRD9BRD7NTRK1FFAR2 | |
| SCHEMBL5785205 | 0.94 | CRHR1 (0.42) | CRHR1NTRK1APLNR | |
| SCHEMBL6498303 | 0.94 | CRHR1 (0.42) | CRHR1NTRK1APLNR | |
| SCHEMBL5785202 | 0.94 | CRHR1 (0.42) | CRHR1NTRK1APLNR | |
| SCHEMBL6498138 | 0.90 | CRHR1 (0.44) | CRHR1BRD9BRD7NTRK1 | |
| SCHEMBL6498553 | 0.90 | CRHR1 (0.41) | CRHR1BRD9BRD7NTRK1FFAR2 | |
| SCHEMBL5783443 | 0.90 | CRHR1 (0.41) | CRHR1BRD9BRD7NTRK1FFAR2 | |
| SCHEMBL5783440 | 0.90 | CRHR1 (0.41) | CRHR1BRD9BRD7NTRK1FFAR2 | |
| SCHEMBL5781075 | 0.87 | CRHR1 (0.46) | CRHR1APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020601-A1 | Novel pyrazinones as CRF1 receptor antagonists | PFIZER INC | 2005-01-27 | — | — | US | claimed |
| EP-1626965-A1 | PYRAZINONES AS CRF1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CNS DISORDERS | Pharmacia & Upjohn Company LLC (US) | 2006-02-22 | — | — | EP | disclosed |
| US-20050020601-A1 | Novel pyrazinones as CRF1 receptor antagonists | PFIZER INC | 2005-01-27 | — | — | US | disclosed |
| WO-2004099161-A1 | PYRAZINONES AS CRF1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CNS DISORDERS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020601-A1 | Novel pyrazinones as CRF1 receptor antagonists | CRHR1, CRHR2, CRH | CRHR1 1/4885BRD9 3792/4885BRD7 3101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.